Linked Life Data

17964009

Source:http://linkedlifedata.com/resource/pubmed/id/17964009

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
49
pubmed:dateCreated
2007-11-20
pubmed:abstractText
HIV-infected children are vulnerable to infections by vaccine preventable pathogens. However, they have poorer responses to childhood immunization than healthy children. The objectives of this study are to determine the prevalence of Japanese encephalitis (JE) protective antibody in HIV-infected children with immune recovery after highly active antiretroviral therapy (HAART) and evaluate response to JE revaccination. JE neutralizing antibody titer of plasma was determined by a plaque reduction neutralization assay. An antibody titer of more than 1:10 was defined as protective antibody. Children who did not have protective antibody to JE were enrolled to receive a two-dose JE revaccination during the study. There were 96 children with mean age of 9.7 years (S.D. 2.6) and mean CD4 percentage of 25 (S.D. 5) who participated in the study. Forty-four children (46%) had protective antibody to JE. A two-dose JE revaccination was administered to 50 children who did not have JE antibody. At 1 month after revaccination, 44 children (88%) developed protective antibody. This study demonstrated that there is a low prevalence of JE protective antibody in HIV-infected children despite history of JE primary childhood vaccination. However, the majority of HIV-infected children with immune recovery after HAART can develop protective antibody after JE revaccination.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
28
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8257-61
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
pubmed:affiliation
Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't